SanBio Company Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNBIF research report →
Companywww.sanbio.jp
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
- CEO
- Keita Mori
- IPO
- 2015
- Employees
- 29
- HQ
- Tokyo, JP
Price Chart
Valuation
- Market Cap
- $1.28B
- P/E
- -30.11
- P/S
- 0.00
- P/B
- 8.50
- EV/EBITDA
- -27.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -88.92%
- ROIC
- -22.33%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,842,146,194 · -33.32%
- EPS
- $-52.63 · -25.76%
- Op Income
- $-3,794,349,976
- FCF YoY
- -6.37%
Performance & Tape
- 52W High
- $16.45
- 52W Low
- $3.85
- 50D MA
- $16.45
- 200D MA
- $16.45
- Beta
- 0.31
- Avg Volume
- 473.748
Get TickerSpark's AI analysis on SNBIF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SNBIF Coverage
We haven't published any research on SNBIF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SNBIF Report →